REFERENCES
1. Saha S, Pradhan N, B N, Mahadevappa R, Minocha S, Kumar S. Cancer plasticity: investigating the causes for this agility. Semin Cancer Biol 2023;88:138-56.
2. Pérez-González A, Bévant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer 2023;4:1063-82.
3. Gu Y, Zhang Z, Ten Dijke P. Harnessing epithelial-mesenchymal plasticity to boost cancer immunotherapy. Cell Mol Immunol 2023;20:318-40.
4. Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther 2020;5:28.
5. Lou Y, Diao L, Cuentas ER, et al. Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 2016;22:3630-42.
6. Mahmoudian RA, Mozhgani S, Abbaszadegan MR, Mokhlessi L, Montazer M, Gholamin M. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC. J Mol Histol 2021;52:597-609.
7. Mak MP, Tong P, Diao L, et al. A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial-to-mesenchymal transition. Clin Cancer Res 2016;22:609-20.
8. Kolijn K, Verhoef EI, Smid M, et al. Epithelial-mesenchymal transition in human prostate cancer demonstrates enhanced immune evasion marked by IDO1 expression. Cancer Res 2018;78:4671-9.
9. Hu Z, Cunnea P, Zhong Z, et al. The Oxford classic links epithelial-to-mesenchymal transition to immunosuppression in poor prognosis ovarian cancers. Clin Cancer Res 2021;27:1570-9.
10. Tiwari JK, Negi S, Kashyap M, Nizamuddin S, Singh A, Khattri A. Pan-cancer analysis shows enrichment of macrophages, overexpression of checkpoint molecules, inhibitory cytokines, and immune exhaustion signatures in emt-high tumors. Front Oncol 2021;11:793881.
11. Chen L, Gibbons DL, Goswami S, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014;5:5241.
12. Zhang J, Hu Z, Horta CA, Yang J. Regulation of epithelial-mesenchymal transition by tumor microenvironmental signals and its implication in cancer therapeutics. Semin Cancer Biol 2023;88:46-66.
13. Tripathi SC, Peters HL, Taguchi A, et al. Immunoproteasome deficiency is a feature of non-small cell lung cancer with a mesenchymal phenotype and is associated with a poor outcome. Proc Natl Acad Sci U S A 2016;113:E1555-64.
14. Taki M, Abiko K, Ukita M, et al. Tumor immune microenvironment during epithelial-mesenchymal transition. Clin Cancer Res 2021;27:4669-79.
15. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y. Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 2009;15:195-206.
16. Kudo-Saito C, Shirako H, Ohike M, Tsukamoto N, Kawakami Y. CCL2 is critical for immunosuppression to promote cancer metastasis. Clin Exp Metastasis 2013;30:393-405.
17. Akalay I, Janji B, Hasmim M, et al. Epithelial-to-mesenchymal transition and autophagy induction in breast carcinoma promote escape from T-cell-mediated lysis. Cancer Res 2013;73:2418-27.
18. Xiao M, Hasmim M, Lequeux A, et al. Epithelial to mesenchymal transition regulates surface PD-L1 via CMTM6 and CMTM7 induction in breast cancer. Cancers 2021;13:1165.
19. Dongre A, Rashidian M, Reinhardt F, et al. Epithelial-to-mesenchymal transition contributes to immunosuppression in breast carcinomas. Cancer Res 2017;77:3982-9.
20. Dongre A, Rashidian M, Eaton EN, et al. Direct and indirect regulators of epithelial-mesenchymal transition-mediated immunosuppression in breast carcinomas. Cancer Discov 2021;11:1286-305.
21. Taki M, Abiko K, Baba T, et al. Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. Nat Commun 2018;9:1685.
22. Hsu DS, Wang HJ, Tai SK, et al. Acetylation of snail modulates the cytokinome of cancer cells to enhance the recruitment of macrophages. Cancer Cell 2014;26:534-48.
23. Noman MZ, Van Moer K, Marani V, et al. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT. Oncoimmunology 2018;7:e1345415.
24. Guo Y, Lu X, Chen Y, et al. Zeb1 induces immune checkpoints to form an immunosuppressive envelope around invading cancer cells. Sci Adv 2021;7:eabd7455.
25. Xu J, Yang X, Pan J, Fan H, Mei J, Hua D. Biochanin A suppresses tumor progression and PD-L1 expression via inhibiting ZEB1 expression in colorectal cancer. J Oncol 2022;2022:3224373.
26. Takamaru N, Fukuda N, Akita K, Kudoh K, Miyamoto Y. Association of PD-L1 and ZEB-1 expression patterns with clinicopathological characteristics and prognosis in oral squamous cell carcinoma. Oncol Lett 2022;23:75.
27. Ortiz-Cuaran S, Swalduz A, Foy JP, et al. Epithelial-to-mesenchymal transition promotes immune escape by inducing CD70 in non-small cell lung cancer. Eur J Cancer 2022;169:106-22.
28. Plaschka M, Benboubker V, Grimont M, et al. ZEB1 transcription factor promotes immune escape in melanoma. J Immunother Cancer 2022;10:e003484.
29. da Silva SD, Marchi FA, Su J, et al. Co-overexpression of TWIST1-CSF1 is a common event in metastatic oral cancer and drives biologically aggressive phenotype. Cancers 2021;13:153.
30. Low-Marchelli JM, Ardi VC, Vizcarra EA, van Rooijen N, Quigley JP, Yang J. Twist1 induces CCL2 and recruits macrophages to promote angiogenesis. Cancer Res 2013;73:662-71.
31. Dhanasekaran R, Baylot V, Kim M, et al. MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity. Elife 2020;9:e50731.
32. Rouzbahani E, Majidpoor J, Najafi S, Mortezaee K. Cancer stem cells in immunoregulation and bypassing anti-checkpoint therapy. Biomed Pharmacother 2022;156:113906.
33. Sipos F, Műzes G. Cancer stem cell relationship with pro-tumoral inflammatory microenvironment. Biomedicines 2023;11:189.
34. Luo Y, Xu WB, Ma B, Wang Y. Novel stemness-related gene signature predicting prognosis and indicating a different immune microenvironment in HNSCC. Front Genet 2022;13:822115.
35. Zheng H, Liu H, Li H, et al. Characterization of stem cell landscape and identification of stemness-relevant prognostic gene signature to aid immunotherapy in colorectal cancer. Stem Cell Res Ther 2022;13:244.
36. Yang W, Li Y, Gao R, Xiu Z, Sun T. MHC class I dysfunction of glioma stem cells escapes from CTL-mediated immune response via activation of Wnt/β-catenin signaling pathway. Oncogene 2020;39:1098-111.
37. Di Tomaso T, Mazzoleni S, Wang E, et al. Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010;16:800-13.
38. Luo S, Yang G, Ye P, et al. Macrophages are a double-edged sword: molecular crosstalk between tumor-associated macrophages and cancer stem cells. Biomolecules 2022;12:850.
39. Cardinale V, Renzi A, Carpino G, et al. Profiles of cancer stem cell subpopulations in cholangiocarcinomas. Am J Pathol 2015;185:1724-39.
40. Wu HJ, Chu PY. Role of cancer stem cells in cholangiocarcinoma and therapeutic implications. Int J Mol Sci 2019;20:4154.
41. Liang N, Yang T, Huang Q, et al. Mechanism of cancer stemness maintenance in human liver cancer. Cell Death Dis 2022;13:394.
42. Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol 2020;17:557-88.
43. Vaquero J, Lobe C, Tahraoui S, et al. The IGF2/IR/IGF1R Pathway in tumor cells and myofibroblasts mediates resistance to egfr inhibition in cholangiocarcinoma. Clin Cancer Res 2018;24:4282-96.
44. Lobe C, Vallette M, Arbelaiz A, et al. Zinc finger e-box binding homeobox 1 promotes cholangiocarcinoma progression through tumor dedifferentiation and tumor-stroma paracrine signaling. Hepatology 2021;74:3194-212.
45. Shuang ZY, Wu WC, Xu J, et al. Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. Cancer Lett 2014;354:320-8.
46. Qian Y, Yao W, Yang T, et al. aPKC-ι/P-Sp1/Snail signaling induces epithelial-mesenchymal transition and immunosuppression in cholangiocarcinoma. Hepatology 2017;66:1165-82.
47. Bian J, Fu J, Wang X, et al. Characterization of immunogenicity of malignant cells with stemness in intrahepatic cholangiocarcinoma by single-cell RNA sequencing. Stem Cells Int 2022;2022:3558200.
48. Raggi C, Correnti M, Sica A, et al. Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages. J Hepatol 2017;66:102-15.
49. Wang X, Golino JL, Hawk NV, Xie C. Reciprocal interaction of cancer stem cells of cholangiocarcinoma with macrophage. Stem Cell Rev Rep 2023;19:2013-23.
50. Chen Z, Li H, Li Z, et al. SHH/GLI2-TGF-β1 feedback loop between cancer cells and tumor-associated macrophages maintains epithelial-mesenchymal transition and endoplasmic reticulum homeostasis in cholangiocarcinoma. Pharmacol Res 2023;187:106564.
51. Martin-Serrano MA, Kepecs B, Torres-Martin M, et al. Novel microenvironment-based classification of intrahepatic cholangiocarcinoma with therapeutic implications. Gut 2023;72:736-48.
52. Zhang M, Yang H, Wan L, et al. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol 2020;73:1118-30.
53. Wang X, Eichhorn PJA, Thiery JP. TGF-β, EMT, and resistance to anti-cancer treatment. Semin Cancer Biol 2023;97:1-11.
54. Yang T, Deng Z, Xu L, et al. Macrophages-aPKC(ɩ)-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma. J Exp Clin Cancer Res 2022;41:23.
55. Lin Y, Cai Q, Chen Y, et al. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Hepatology 2022;75:28-42.
56. Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling. Cancer Res 2016;76:4124-35.
57. Song G, Shi Y, Meng L, et al. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma. Nat Commun 2022;13:1642.
58. Cao L, Bridle KR, Shrestha R, Prithviraj P, Crawford DHG, Jayachandran A. CD73 and PD-L1 as potential therapeutic targets in gallbladder cancer. Int J Mol Sci 2022;23:1565.
59. Greten TF, Schwabe R, Bardeesy N, et al. Immunology and immunotherapy of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol 2023;20:349-65.
60. Tomlinson JL, Valle JW, Ilyas SI. Immunobiology of cholangiocarcinoma. J Hepatol 2023;79:867-75.
61. Paillet J, Kroemer G, Pol JG. Immune contexture of cholangiocarcinoma. Curr Opin Gastroenterol 2020;36:70-6.
62. Job S, Rapoud D, Dos Santos A, et al. Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma. Hepatology 2020;72:965-81.
63. Kawamoto M, Umebayashi M, Tanaka H, et al. Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. Anticancer Res 2018;38:2739-48.
64. Tabatabaee A, Nafari B, Farhang A, et al. Targeting vimentin: a multifaceted approach to combatting cancer metastasis and drug resistance. Cancer Metastasis Rev 2023:Online ahead of print.
